Clinicogenetic study of mutations in <i>LRRK2</i> exon 41 in Parkinson's disease patients from 18 countries
Hiroyuki Tomiyama(German Center for Neurodegenerative Diseases), Nobutaka Hattori(RIKEN Center for Brain Science), Ruth Djaldetti(Rabin Medical Center), Manabu Funayama(Juntendo University), Tatsushi Toda(Osaka University), Yoko Imamichi(Juntendo University), Rivka Inzelberg(Tel Aviv Sourasky Medical Center), Matthew J. Farrer(University of British Columbia), Shinichiro Kubo(Juntendo University), Rim Amouri(Tunis University), Yoshikuni Mizuno(Juntendo University), Hiroaki Miyajima(Koei Chemical (Japan)), Mei Wang(Juntendo University), Kenichi Sato(Juntendo University), Tatsuya Hattori, Kazuko Hasegawa(National Sagamihara Hospital), Fayçal Hentati(National Institute of Neurology Mongi-Ben Hamida), Fumiya Obata, Hiroyo Yoshino(Juntendo University), Yasuko Hatano, Eldad Melamed(Rabin Medical Center), Koichi Mizoguchi(National Epilepsy Center), N. Gouider‐Khouja(National Institute of Neurology Mongi-Ben Hamida), Chin‐Song Lu(Chang Gung Memorial Hospital), Yuanzhe Li(Juntendo University)
Cited by 111
Related Papers
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
|Nature Genetics|2000|2k
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
|The Journal of Cell Biology|2010|1.9k